The widespread condemnation of drastic price increases on life-saving drugs highlights our growing dependency on and vulnerability to international pharmaceutical conglomerates. However, aren’t the interests of the public supposed to supersede the pursuit of private profit?

In his new work, Private Profits versus Public Policy, Joel Lexchin addresses this question as he examines how public policy with respect to the pharmaceutical industry has evolved in Canada over the past half century. Although the Canadian government is supposed to regulate the industry to serve the needs of public health, waves of deregulatory reforms and intellectual property rights legislation have shifted the balance of power in favour of these companies’ quest for profit. Joel Lexchin offers a series of recommendations to tip the scale back in the public’s favour. This enlightening work is the first book that deals exclusively with the pharmaceutical industry in Canada in over thirty years.

Joel Lexchin is an internationally-recognized expert in pharmaceutical policy. He received his MD from the University of Toronto in 1977 and has spent over thirty years working as an emergency physician in Hamilton and Toronto. He is a Professor Emeritus in the School of Health Policy and Management at York University where he taught health policy from 2001 to 2016. He has been an advocate for change in pharmaceutical policy for thirty-five years, has appeared before numerous parliamentary committees, and has authored or co-authored over 150 articles about all aspects of how medicines are developed and used. His most recent book Private Profits versus Public Policy: The Pharmaceutical Industry and the Canadian State was published in early 2016.

Joel Lexchin's profile page